pershing
Allergan rejects Valeant – again
June 11, 2014Research and Development, Sales and Marketing Allergan, Botox, Valeant, pershing, pharma
Allergan and Valeant Pharmaceuticals International are continuing their stately dance around one another – and in the latest move the …
Valeant makes $45.7 billion Allergan offer
April 23, 2014Sales and Marketing Allergan, Botox, GSK, Novartis, Pfizer, Valeant, merger, pershing
In the latest proposal in a flurry of merger and acquisition activity in the pharma sector, Valeant Pharmaceuticals International wants …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
